Literature DB >> 6103055

p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo.

A L Green, M A El Hait.   

Abstract

p-Methoxyamphetamine is over 20 times as potent as (+)-amphetamine as an inhibitor of 5-HT oxidation by monoamine oxidase in mouse brain in vitro, with a Ki value of 0.22 microM. It is highly selective towards A-type monoamine oxidase and possesses only weak activity against the B-type enzyme (Ki value about 500 microM with benzylamine as substrate and solubilized rat liver mitochondria as enzyme source). It is 10 times more active than (+)-amphetamine in protecting mouse brain monoamine oxidase from inhibition by phenelzine in vivo. o-Methoxy- and m-methoxyamphetamines inhibit monoamine oxidase both in vitro and in vivo with potencies comparable with, or less than that of (+)-amphetamine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6103055     DOI: 10.1111/j.2042-7158.1980.tb12909.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  9 in total

1.  (+/-)-1-(2,5-Dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2), a novel putative anxiolytic agent lacking affinity for benzodiazepine sites and serotonin-1A receptors.

Authors:  M Reyes-Parada; C Scorza; V Romero; R Silveira; J H Medina; D Andrus; D E Nichols; B K Cassels
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

2.  "Designer" amphetamines: effects on behavior and monoamines with or without reserpine and/or alpha-methyl-para-tyrosine pretreatment.

Authors:  M T Martin-Iverson; N Yamada; A W By; B A Lodge
Journal:  J Psychiatry Neurosci       Date:  1991-12       Impact factor: 6.186

Review 3.  New psychoactive substances: Pharmacology influencing UK practice, policy and the law.

Authors:  David Nutt
Journal:  Br J Clin Pharmacol       Date:  2020-02-04       Impact factor: 4.335

4.  Catalytic and inhibitor binding properties of zebrafish monoamine oxidase (zMAO): comparisons with human MAO A and MAO B.

Authors:  Milagros Aldeco; Betül Kacar Arslan; Dale E Edmondson
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2011-02-23       Impact factor: 2.231

5.  Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine.

Authors:  K M Hegadoren; M T Martin-Iverson; G B Baker
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

6.  Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat brain.

Authors:  A L Ask; I Fagervall; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

7.  5-(5-Aryl-1,3,4-oxadiazole-2-carbonyl)furan-3-carboxylate and new cyclic C-glycoside analogues from carbohydrate precursors with MAO-B, antimicrobial and antifungal activities.

Authors:  Mohamed Mohamed El-Sadek; Seham Yassen Hassan; Nagwa Said Abd El-Dayem; Galila Ahmed Yacout
Journal:  Molecules       Date:  2012-06-07       Impact factor: 4.411

Review 8.  Amphetamine Derivatives as Monoamine Oxidase Inhibitors.

Authors:  Miguel Reyes-Parada; Patricio Iturriaga-Vasquez; Bruce K Cassels
Journal:  Front Pharmacol       Date:  2020-01-23       Impact factor: 5.810

9.  Alterations of Mitochondrial Structure in Methamphetamine Toxicity.

Authors:  Paola Lenzi; Francesca Biagioni; Carla L Busceti; Gloria Lazzeri; Maico Polzella; Alessandro Frati; Michela Ferrucci; Francesco Fornai
Journal:  Int J Mol Sci       Date:  2022-08-10       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.